HemaQuest enrolls first patient in phase II study of HQK-1001
California-based HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, have enrolled the first patient in a randomized multi-dose phase II study of HQK-1001 in patients with sickle cell disease.
The study, which is being conducted in the U.S., Canada, Jamaica, Egypt and Lebanon, is expected to enroll approximately 50 patients. The primary objective is safety and tolerability of HQK-1001. There are several secondary objectives including an increase in fetal hemoglobin production.